Associated Papers
Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations.
Leini R et al.
Scientific Reports, 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
Riedl JM et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_3.xlsx › KRAS_G12D_LOF_DMS_Screens
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
Rubinson DA et al.
Cancer Discovery, 2024
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA et al.
Cancer Research, 2023
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
35650444 (PubMed )
Supplement: 41586_2022_4785_MOESM12_ESM.xlsx › MDS
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
35284050 (PubMed )
Supplement: mmc1.docx
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.
Haza KZ et al.
Nature Communications, 2021
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Select a paper to view details